Development and Validation of Tafenoquine by HPLC Technique along with stress degradation study of Tafenoquine
Abstract
The most prevalent parasite disease in humans is malaria. According to estimates, 3 billion individuals worldwide are at danger of developing this illness. For the quantitative detection of tafenoquine, a brand-new, quick, and accurate stability-indicating high performance liquid chromatographic method was created and validated. On an Inertsil ODS-3V column (150 mm 4.6 mm, 5.0 m) with mobile phase methanol and water (80:20) at a flow rate of 1 mL/min, effective chromatographic separation was accomplished. The analyte was seen using a photo-diode array detector at a wavelength of 254 nm. Tafenoquine was subjected to acidic, basic, oxidative, thermal, and photolytic conditions in order to force its destruction. The peaks of the degradation products produced were distinct from those of tafenoquine and showed the specificity and stability of the technique. The method was also validated using criteria like specificity, precision, linearity, accuracy, and robustness in accordance with the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The major goal of this research was to create a fast, sensitive, and stable HPLC method for analysing and assessing the purity and stability of tafenoquine in formulations.
Keywords:
Tafenoquine, HPLC, Stability-indicating, Forced degradation, ICHDOI
https://doi.org/10.25004/IJPSDR.2022.140405References
Milhouse WK, Bruecker RP, Theorides AD, Schuster BG. Programs and Abstracts of the 31st Interscience Conference On Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC, 1991, p. 161. 4.
Milhouse WK, Robinson BL, Bruecker RP, Schuster BG, Peters W. Program and Abstracts of the 41st Annual An accurate and precise LC–MS–MS assay using Meeting of the American Society of Tropical Medicine and Hygiene, 1992, p. 89
Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First-time-in-humans safety and pharmacokinetics of WR 238 605, a new antimalarial. Am J Trop Med Hyg 1998; 58: 645±649.
Peters W, Robinson BL, Milhous WK. The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238 605. Ann Trop Med Parasitol 1993; 87: 547±552.
Milhous WK, Brueckner RP, Theoharides AD, Schuster BG. Preclinical ef®cacy of WR 238 605. In Program and Abstracts of the 31st Interscience Conference on Antimcrobial Agents and Chemotherapy. American Society of Microbiology, Washington, DC, USA: 1992, Abstract 376.
Milhous WK, Theoharides AD, Schuster BG, et al. New alternatives to primaquine. In Program and Abstracts of the Xiith International Congress for Tropical Medicine and Malaria. Amsterdam, The Netherlands: 1988, Abstract FrS-12±4.
Heisy GE, Milhous WK, Hansuklarita P, Theoharides AD, Schuster BG, Davidson DE. Radical curative properties of WR 238 605. In Program and Abstracts of the American Society of Tropical Medicine and Hygiene. Washington, DC, USA: 1988, Abstract 323.
Kyle DE. In vitro antimalarial activity of etaquine (WR 238605). In Symposium on Etaquine Held in Association with the 46th Annual Meeting of the American Society of Tropical Medicine and Hygiene: 1997, December 7±11; Florida, USA.
Brueckner RP, Coster T, Wesche DL, Shmuklarsky M, Schuster BG. Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238 605, a new 8-aminoquinoline antimalarial. Antimicrob Agents Chemother 1998; 42: 1293±1294.
Shanks D. Etaquine (WR 238605) for the prophylaxis of Plasmodium falciparum malaria. In Symposium on Etaquine Held in Association with the 46th Annual Meeting of the American Society of Tropical Medicine and Hygiene: 1997, December 7±11; Florida, USA.
Walsh DS, Looareesuwan S, Wilairatana P, et al. Randomized dose-ranging study of the safety and efficacy of WR 238 605 (tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis 1999; 180: 1282-1287.
Published
Abstract Display: 784 
PDF Downloads: 635 
